What is ALEC's market cap?

$254.58M, based on the Nov 4 close of $2.28.

Does Alector pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ALEC is sold short?

10.3M shares, 11.1% of float, as of Oct 15, 2026.

What sector is ALEC in?

Healthcare, in the Biotechnology industry.

NASDAQ · ALECHealthcareBiotechnology

Alector, Inc. Common Stock (ALEC)

$2.28+11.22%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$2.28▲ 72.73% in range

Nov 4, 2025Low $1.14 · High $2.72Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Alector closed at $2.28 on Nov 4, up 11.22%, 16.2% below its 52-week closing high. Volume of 1.5M shares was 0.58× its 20-day average (below normal).

Split-adjusted performance: +26.0% over one month, -11.3% over six months, +58.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.32M, down 57.8% from a year earlier, with a net margin of -692.5%.

Short interest was 10.3M shares at the Oct 15 settlement, up 66.8% from the prior report (11.1% of float, 1.0 days to cover).

Market cap$254.6M111.7M shares

Revenue · quarter$3.3M−57.8% YoY

Diluted EPS$-0.21—

P/E · TTM—P/S 18.4×

Net margin-692.5%Gross 100.0%

Dividend yieldNone

52-week range1.14 – 2.72−16.2% from high

Volume1.5M0.58× 20-day avg

Volatility · 60d85.5%Annualised

Short % of float11.1%1.0 days to cover

Net cash$162.9MCash $172.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.3%1M +26.0%3M +24.6%6M −11.3%YTD +46.2%1Y +58.3%3Y −55.8%5Y −89.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum59

Revenue growth21

Net margin36

Value (low P/E)—

Size50

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short10.3M+66.8% vs prior

Days to cover1.0Settled Oct 15

% of float11.1%

Short vol. 10d43.6%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ALECAlector	$2.28	+11.22%	−11.3%	−57.8%	−692.5%	—	$254.6M
FATEFate Therapeutics	$2.09	+2.45%	−8.7%	+9.2%	−1448.6%	—	$250.4M	Compare
LCTXLineage Cell Therapeutics	$1.03	+1.98%	−28.0%	−61.3%	138.6%	—	$260.5M	Compare
LXEOLexeo Therapeutics	$3.23	+3.86%	−48.2%	—	—	—	$265.1M	Compare
CABACabaletta Bio	$1.42	0.00%	−61.9%	—	—	—	$240.8M	Compare
PROKProKidney	$1.12	+4.67%	−42.9%	−32.1%	−18948.0%	—	$234.1M	Compare
DTILPrecision BioSciences	$8.12	+16.50%	+8.0%	−100.0%	—	—	$224.1M	Compare
SABSSAB Biotherapeutics	$3.18	+1.92%	−16.3%	—	—	—	$289.3M	Compare
OCGNOcugen	$0.8745	+17.35%	−39.9%	+8.4%	−1671.8%	—	$296.6M	Compare

News about Alector

All news →

No recent articles focused on Alector. 1 articles mention it in passing.

Quick answers

What does Alector do?: Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
What is ALEC's market cap?: $254.58M, based on the Nov 4 close of $2.28.
Does Alector pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ALEC is sold short?: 10.3M shares, 11.1% of float, as of Oct 15, 2026.
What sector is ALEC in?: Healthcare, in the Biotechnology industry.

About Alector

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

HQ: South San Francisco, CA103 employeesListed Feb 7, 2019alector.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology